logo
Book a meeting
miRecule

Mi Recule

Biotechnology, 704 Quince Orchard Road, Gaithersburg, Maryland, 20878, United States, 1-10 Employees

mirecule.com

  • facebook
  • LinkedIn

Who is MIRECULE

We develop first-in-class RNA-based therapies, with lead programs in Head & Neck Squamous Cell Carcinoma (HNSCC) and Facioscalpulohumeral Muscular Dystrophy (FSHD). Our approach to drug d...

Read More

lock icon Get Full Access
map
  • 704 Quince Orchard Road, Gaithersburg, Maryland, 20878, United States Headquarters: 704 Quince Orchard Road, Gaithersburg, Maryland, 20878, United States
  • 2016 Date Founded: 2016
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: Under $1 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2836 | NAICS Code: 541714 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from MIRECULE

miRecule Org Chart and Mapping

Employees
Ashwin Kulkarni

Ashwin Kulkarni

Co-Founder, Controller

Aallya Nascimento

Aallya Nascimento

Associate Researcher

David Vance

David Vance

Head of Intellectual Property

Fu-An Kang

Fu-An Kang

Vice President Research

Charles Marusak

Charles Marusak

Scientist

See Full Org Chart arrow
email-formate-icon
View Email Formats for miRecule
arrow
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

Join Now

crown-icon Free credits every month

Frequently Asked Questions Regarding MiRecule

Answer: miRecule's headquarters are located at 704 Quince Orchard Road, Gaithersburg, Maryland, 20878, United States

Answer: miRecule's official website is https://mirecule.com

Answer: miRecule's revenue is Under $1 Million

Answer: miRecule's SIC: 2836

Answer: miRecule's NAICS: 541714

Answer: miRecule has 1-10 employees

Answer: miRecule is in Biotechnology

Answer: miRecule contact info: Phone number: Website: https://mirecule.com

Answer: We develop first-in-class RNA-based therapies, with lead programs in Head & Neck Squamous Cell Carcinoma (HNSCC) and Facioscalpulohumeral Muscular Dystrophy (FSHD). Our approach to drug design revolves around using genomic patient data to create highly tailored therapeutics the right drug for the right patient. Our proprietary DREAmiRTM platform utilizes genomic and outcome data from thousands of patients to identify underlying genetic changes that cause their disease, and then creates a novel RNA therapeutic that can directly target and fix that genetic abnormality.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access